The short version of 合成肽 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-02. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Dose—From 10 to 30 drops for adults, according to the strength of the patient, or severity of the pain. Thirty drops of this laudanum will be equal to one grain of opium. And this is a much better way to prepare it than putting the opium into alcohol, or any other spirits alone, for in that case much of the opium does not dissolve." The remaining three formulas are copied from an 1890 publication of the day:
A Loner addresses the themes of depression and the need for isolation, as Chanut was affected by these issues during the lockdown period, which coincided with the writing of the album. "A Thousand Miles Away", the last song on the album, marked the onset of Chanut's depression; the lyrics he wrote were about his father's death. David stated that A Loner's musical approach and themes addressed are "purely personal" and that the lyrics "evoke despair without making it an end in itself." "Dark, brooding and unapologetically downbeat on record", wrote Kerrang!'s Sam Law. In 2025, Toufouti stated that he found it interesting to elaborate on a sad individual or subject, as he felt there was material to develop. Saddiction continued in the vein of A Loner by being "more personal, more introspective", said Chanut. Before entering the studio, Toufouti slightly reworked the lyrics of "Neglect" to evoke his relationship with his father, who had just passed away. Lemaire wrote that the song's title, "Kowloon Lights", as well as the large block of buildings on the front cover of Sadditcion, point to a city theme. Chanut responded by elaborating on the feeling of loneliness in crowds, particularly in large cities like Paris, as well as on the mobile phone culture where everyone is focused on their own things. "Kowloon Lights" refers to the former densely populated enclave within the Hong Kong colony. Chanut commented on the grey buildings that made up the city and its colourful neon lights, often depicted in many Hong Kong films of the 1980s.
Arrived from Mexico on the blessed ground of this republic, whose executive powers were placed in your hands, I feel it my pleasant duty to present my respects and express my high admiration for your writings, your actions, and the liberalism of your ideas, which have inspired me from my earliest youth. I flatter myself in the expectation of expressing my sentiments orally to you, remitting at the same time the attached parcel, which my friend the Consul of the United States in Havana asked me to send to you[...] For moral reasons I could not resist seeing the United States and enjoying the consoling aspects of a people who under stand the precious gift of Liberty. I hope to be able to present my personal respects and admiration to one who contemplates philosophically the troubles of two continents. [...] I am quite unaware whether you know of me already through my work on galvanism and my publications in the memoirs of the Institut National in Paris. As a friend of science, you will excuse the indulgence of my admiration. I would love to talk to you about a subject that you have treated so ingeniously in your work on Virginia, the teeth of mammoth which we too dis covered in the Andes[...] During his wait for a response from President Jefferson, Humboldt was honored by the American Philosophical Society, of which Jefferson was the President. This society, founded in 1743 by Benjamin Franklin, was a center for scientific inquiry in the Republic. Humboldt mingled with members such as Dr.
Sources: en.wikipedia.org
Marcus (1948), cardiologist and professor at University of Arizona Medical Center Frederick Reif (1948), professor of physics and psychology at Carnegie Mellon University, recipient of the 1994 Robert A. Millikan Award Robert Neil Butler (1949), president of the International Longevity Center and winner of the Pulitzer Prize for General Nonfiction William Chinowsky (1949), astrophysicist and professor at the University of California, San Diego Edgar Housepian (1949), neurosurgeon, co-founder of the Fund for Armenian Relief Benjamin Widom (1949), professor of chemistry at Cornell University; recipient of the Boltzmann Medal in 1998 Noel Corngold (1950), physicist at California Institute of Technology Edwin Kessler (1950), first director of the National Severe Storms Laboratory Gerald Weissmann (1950), cell biologist, liposome inventor, essayist Arthur H. Westing (1950), ecologist and researcher at Stockholm International Peace Research Institute Leon Cooper (1951), winner of the Nobel Prize in Physics in 1972 Richard A. Gardner (1952), psychiatrist known for researching Parental alienation syndrome Edgar Haber (1952), former president of Bristol-Myers Squibb and professor at Harvard Medical School Donald E.
=== Growth factors and proteolytic enzymes === Chronic wounds also differ in makeup from acute wounds in that their levels of proteolytic enzymes such as elastase. and matrix metalloproteinases (MMPs) are higher, while their concentrations of growth factors such as Platelet-derived growth factor and Keratinocyte Growth Factor are lower. Since growth factors (GFs) are imperative in timely wound healing, inadequate GF levels may be an important factor in chronic wound formation. In chronic wounds, the formation and release of growth factors may be prevented, the factors may be sequestered and unable to perform their metabolic roles, or degraded in excess by cellular or bacterial proteases. Chronic wounds such as diabetic and venous ulcers are also caused by a failure of fibroblasts to produce adequate ECM proteins and by keratinocytes to epithelialize the wound. Fibroblast gene expression is different in chronic wounds than in acute wounds. Though all wounds require a certain level of elastase and proteases for proper healing, too high a concentration is damaging. Leukocytes in the wound area release elastase, which increases inflammation, destroys tissue, proteoglycans, and collagen, and damages growth factors, fibronectin, and factors that inhibit proteases. The activity of elastase is increased by human serum albumin, which is the most abundant protein found in chronic wounds. However, chronic wounds with inadequate albumin are especially unlikely to heal, so regulating the wound's levels of that protein may in the future prove helpful in healing chronic wounds.
The Institut National de la Recherche Biomédicale (INRB) is the national medical research organization of the Democratic Republic of the Congo. The responsible ministry is the Ministry of Scientific Research and Technology. The National Biomedical Research Institute (INRB) was founded in 1984. It is a 70,000 m² establishment. It has been a collaborating center of the World Health Organization since 2018, headed by Professor Jean-Jacques Muyembe-Tamfum, MD, PhD, and serving as a national biomedical research laboratory for the Ministry of Health of the Democratic Republic of Congo (DRC). It is a multidisciplinary institute which collectively has hundreds of years of experience in the identification, treatment and prevention of diseases in the DRC. Its foundations are the performance of medical and biological analyzes, applied and translational research, surveillance of communicable diseases and the promotion of professional growth and development. The INRB has continuously developed and trained high-quality researchers and produced exceptional results. More recently, it has made concrete efforts in terms of control, prevention, and research in response to the current Ebola epidemic. It has continuously brought it's expertise to the government of the DRC in the areas of disease surveillance, prevention and intervention. In 30 years of existence, the INRB has quickly become recognized worldwide and has played an essential role in tropical health research.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.